NFKB1 and myeloid sarcoma: A recent study demonstrated that Sulfasalazine, an anti-inflammatory and immune-modulating drug that improves the outcome of MS patients, inhibited AKT2/NF-κB axis via the ceRNA effect of miR-136-5p and lncRNA HOTAIR in a mouse model of cuprizone-induced demyelination [110].